Sonogenetic Control of Engineered Probiotics for the Treatment of MASH by Modulating the Gut‐Liver Axis
ABSTRACT Metabolic dysfunction‐associated steatohepatitis (MASH) currently lacks effective targeted therapeutics, while interleukin‐22 (IL‐22) as a potential treatment approach faces challenges in the clinical translation due to off‐target risks associated with systemic delivery. To address this limitation, we develope...